Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law
OCEANSIDE, Calif., May 31, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th, 2018.
At the signing President Trump said the following, “With the Right to Try law I’m signing today, patients with life-threatening illnesses will finally have access to experimental treatments that could improve or even cure their conditions. These are experimental treatments and products that have shown great promise, and we weren’t able to use them before. Now we can use them. And oftentimes they’re going to be very successful. It’s an incredible thing.”
“Having successfully completed a Phase 1 Clinical trial in Mexico using our StemVacs cancer platform with ten patients, we are reviewing our data to determine its applicability under this new law. In the previous study no patients had any reportable adverse events associated with the administration of StemVacs,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “We recently announced the licensing of our StemVacs platform to Pan American Cancer Treatment Center in Tijuana Mexico, and we are currently offering cancer treatment in stages 1-4 in both prostate and breast cancer, and we intend to continue offering the platform at Pan Am,” added Mr. Dixon.
“This bill signed into law by President Trump would allow those with potentially terminal diseases to try experimental treatments and bypass the U.S. FDA. As a physician that has watched many promising drugs take up to 15 years for approval, it’s tragic, and this is far too long for dying patients to wait. The StemVacs platform allows TSOI to build custom vaccines for each patient across a wide variety of cancers including prostate, breast, lung, liver, and kidney using dendritic cells from patients, which are activated by our proprietary process enabling the dendritic cells to produce “natural cytokines”, which kill cancer cells,” said Dr. James Veltmeyer, Republican Congressional Candidate and Scientific Advisory Board Member of TSOI.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
- Therapeutic Solutions International, Inc.